Masters candidate in Biostatistics, Yuntian Zuo, will present: “Competing Risk Analysis of Adverse Events for Gemcitabine-antibacterial Treatment on Multiple Discontinued Reasons”

In this project, data from the MPACT cancer trial was used to study the reason patients with pancreatic cancer discontinue from the clinical trial, and whether certain adverse events make patients more likely to discontinue the study. The adverse events are categorized into five distinct groups. Cause-specific Cox Proportional Hazard (Cox-PH) and Accelerated Failure Time (AFT) models are utilized to demonstrate the impact of these adverse events on the hazard, the increase in survival time for patients discontinuing the study for a variety of reasons. Both models employed time-varying covariates, allowing for changes in whether a patient was experiencing an adverse event at a given time, providing a more dynamic and realistic representation of patient experiences over time. Gastrointestinal disorders are associated with an increased risk of patient discontinuation due to adverse events and progressive disease. General disorders and administration site conditions are associated with an increased hazard of patient discontinuation due to progressive disease and toxicity. As gastrointestinal related adverse events increase, there is an increased hazard of discontinuation due to Adverse Events and Progressive Disease. General disorders and administration site conditions and Blood Disorder events increases are associated with heightened discontinuation risks from Toxicity.